Koichi Azuma

17PUBLICATIONS

82CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersImmunogenetics (incl. genetic immunology)Medical biochemistry - amino acids and metabolites

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (17)

Sort by Publication Date:

|May 26, 2026

Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

|Mar 11, 2026

Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors.

Hiroaki Kanemura, Toshiyuki Takehara, Osamu Maenishi

|Mar 31, 2025

Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Shintaro Kanda, Seiji Niho, Takayasu Kurata

|Sep 05, 2024

Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy.

Daiki Murata, Koichi Azuma, Kenta Murotani

|Jan 05, 2024

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.

Makoto Nishio, Shuji Murakami, Hisato Kawakami

|Sep 15, 2023

Survival and biomarkers for cachexia in non-small cell lung cancer receiving immune checkpoint inhibitors.

Daiki Murata, Koichi Azuma, Norikazu Matsuo

Pageof 3

Frequent Collaborators

Takaaki Tokito

Daiki Murata

Haruyasu Murakami

Makoto Nishio

Hiroaki Akamatsu

Kazuto Nishio

Kimio Yonesaka

Tetsuro Sasada

Nobuyuki Yamamoto

Toyoaki Hida

Frequent Collaborators

Takaaki Tokito

Daiki Murata

Haruyasu Murakami

Makoto Nishio